Skystar Bio Pharmaceutical Company Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2013; Reiterates Earnings Guidance of 2013
For the six months, the company reported revenue of $16,865,886 against $16,797,185 a year ago. Income from operations was $5,616,533 against $4,756,505 a year ago. Income before provision for income taxes was $5,481,655 against $4,655,362 a year ago. Net income was $4,463,614 against $3,603,620 a year ago. Diluted earnings per share were $0.59 against $0.48 a year ago.
The company reiterate its fiscal 2013 guidance to be in the range of $40 million to $45 million. The company expects solid revenue growth and expansion in fiscal 2014.